CST China was established in 2008，as China subsidiary（WOFE）to Cell Signaling Technology（CST）USA，serving customers in China and the Asia-Pacific region. Over the past ten years，China’s biomedical research has developed rapidly，thanks to the strong support of the government from financial support to talent introduction. Since 2018，China’s macro-economy has entered a critical period of adjustment aimed at transforming into a period of high-quality growth. The biomedical field is expected to be the industry most likely to produce the next BAT. Since the 11th Five-Year Plan，China has invested heavily in scientific research and R&D projects in innovative drugs and has attracted a large number of overseas talents. This article tells how CST entered China，how best to serve customers and deeply penetrate the Chinese market，set the localization strategic goal and value proposition，how to serve scientists，form in-depth cooperation with academia，industry and so on，and strive for the development process of China’s biomedical innovation，as well as contribute to building an ecosystem for innovation and healthy life.